For Urovant, beating placebo in a pivotal trial of vibegron was the easy part.
Targeting a mechanism of resistance to first-generation BTK inhibitors has caught the attention of biotechs like Arqule, which claimed a major success last week.
An Icer white paper provides ammunition for both PBMs and pharma before the next Capitol Hill hearing.
Fears about flattening Opdivo sales were surely a major driver for Bristol's move for Celgene. To keep growing the checkpoint inhibitor needs some big clinical wins.
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Amarin and Esperion get a chance to reinforce their lipid-lowering candidates, while a Bayer heart failure project gets a high-profile slot despite its discontinuation.
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.
Many in the biopharma sector will rue the departure of Scott Gottlieb, an FDA commissioner who pursed a permissive path for novel drugs at the US regulator. Will his…
Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.